… Three studies have described activating mutations in advanced NSCLC that made
tumours more sensitive to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. …

… In our trial, the response rate of 8.9 percent was similar to rates reported for erlotinib and
gefitinib. Some investigators have reported that responsiveness to EGFR inhibitors correlates …

… ) patients who have failed of gefitinib or erlotinib treatment in … EGFR mutation patients with
the gefitinib or erlotinib treatment, … For patients who previous treated with TKI and later showed …

… no patient was identified whose death was attributed to treatment with erlotinib or gefitinib. …
for the first time that adjuvant therapy with erlotinib or gefitinib in patients with resected lung …

… and erlotinib or gefitinib therapy after the relapse to these EGRF-TKIs was effective and
tolerated in patients … These data suggest that EGFR-TKI treatment beyond progression might be …

… EGFR-mutant NSCLC responded to erlotinib treatment. … -over response to erlotinib after
gefitinib failure in a patient with an activating … Erlotinib was administered as soon as gefitinib was …

… from 24 patients treated with gefitinib, and prospectively for 36 patients treated with erlotinib,
… resistance of lung adenocarcinomas to gefitinib or erlotinib was associated with a second …

… efficacy than gefitinib or erlotinib in first-line treatment of EGFR-… more effective than erlotinib
as second-line treatment of patients with … to that of erlotinib but higher than that of gefitinib. …

… In summary, our results suggest lower rates of CNS progression in EGFR-mutant
advanced NSCLC patients initially treated with gefitinib or erlotinib compared with upfront …

… The efficacy of erlotinib treatment after gefitinib failure in patients with … rate to erlotinib
treatment after gefitinib failure was lower than that to the gefitinib treatment despite all the patients …